Associated Genetic Biomarkers
AT rich interactive domain 2 (ARID; RFX-like) (ARID2) is a gene that encodes a protein that functions in a chromatin remodeling complex to promote gene transcription. Missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame insertions and deletions are observed in cancers such as intestinal cancer, liver cancer, and lung cancer.
ARID2 is altered in 3.33% of all cancers with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, cutaneous melanoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in ARID2 are ARID2 Mutation (3.78%), ARID2 Amplification (0.22%), ARID2 Loss (0.05%), ARID2 R314C (0.05%), and ARID2 S297F (0.04%) .
ARID2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains ARID2 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with ARID2 status in the inclusion eligibility criteria most commonly target melanoma .
The most frequent alteration to serve as an inclusion eligibility criterion is ARID2 Mutation .
Niraparib is the most frequent therapy in trials with ARID2 as an inclusion criteria .
Significance of ARID2 in Diseases
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.